位置:首页 > 蛋白库 > EST2B_XENLA
EST2B_XENLA
ID   EST2B_XENLA             Reviewed;         876 AA.
AC   Q7ZWU7;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   03-AUG-2022, entry version 83.
DE   RecName: Full=Extended synaptotagmin-2-B;
DE            Short=E-Syt2-B;
GN   Name=esyt2-b; Synonyms=fam62b-b;
OS   Xenopus laevis (African clawed frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia;
OC   Batrachia; Anura; Pipoidea; Pipidae; Xenopodinae; Xenopus; Xenopus.
OX   NCBI_TaxID=8355;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Embryo;
RG   NIH - Xenopus Gene Collection (XGC) project;
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, DISRUPTION PHENOTYPE,
RP   AND DOMAIN.
RX   PubMed=20833364; DOI=10.1016/j.devcel.2010.08.007;
RA   Jean S., Mikryukov A., Tremblay M.G., Baril J., Guillou F., Bellenfant S.,
RA   Moss T.;
RT   "Extended-synaptotagmin-2 mediates FGF receptor endocytosis and ERK
RT   activation in vivo.";
RL   Dev. Cell 19:426-439(2010).
CC   -!- FUNCTION: Tethers the endoplasmic reticulum to the cell membrane and
CC       promotes the formation of appositions between the endoplasmic reticulum
CC       and the cell membrane. Binds glycerophospholipids in a barrel-like
CC       domain and may play a role in cellular lipid transport (By similarity).
CC       Plays a role in the rapid internalization of fgfr1 that has been
CC       activated by fgf1 binding; this occurs most likely via the AP-2
CC       complex. Required for normal fgf signaling and the activation of
CC       downstream signaling cascades via its role in the internalization of
CC       activated fgfr1. Required for normal embryonic development via its role
CC       in fgf signaling and the downstream regulation of t/xBRA expression.
CC       {ECO:0000250, ECO:0000269|PubMed:20833364}.
CC   -!- SUBUNIT: Interacts with fgfr1 that has been activated by fgf1 binding.
CC       Interacts (via C2 domains) with the AP-2 complex (via an alpha
CC       subunit). Identified in a complex with the AP-2 complex and fgfr1.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20833364};
CC       Peripheral membrane protein {ECO:0000269|PubMed:20833364}. Endoplasmic
CC       reticulum membrane {ECO:0000250|UniProtKB:A0FGR8}; Multi-pass membrane
CC       protein {ECO:0000255}. Note=Localizes to endoplasmic reticulum-plasma
CC       membrane contact sites (EPCS). Recruited to the cell membrane via the
CC       third C2 domain (By similarity). {ECO:0000250|UniProtKB:A0FGR8}.
CC   -!- DEVELOPMENTAL STAGE: Detected throughout embryonic development. In late
CC       gastrula and neurula stages, mainly expressed in head and dorsolateral
CC       mesoderm, and in eye, cranial neural crest and somites at later stages.
CC       {ECO:0000269|PubMed:20833364}.
CC   -!- DOMAIN: Anchored to the endoplasmic reticulum membrane by a
CC       transmembrane hairpin structure; both N-terminus and C-terminus are
CC       cytoplasmic. {ECO:0000250}.
CC   -!- DOMAIN: The C2 domains mediate lipid and calcium binding. The N-
CC       terminal C2 domain binds calcium ions and is important for calcium-
CC       dependent lipid binding and interaction with membranes. Two calcium
CC       ions are bound at a high-affinity site and a third calcium ion is bound
CC       with lower affinity. May bind up to four calcium ions. In contrast, the
CC       second C2 domain apparently does not bind calcium (By similarity). The
CC       third C2 domain mediates interaction with membranes enriched in
CC       phosphatidylinositol 4,5-bisphosphate and is required for location at
CC       the cell membrane. {ECO:0000250, ECO:0000269|PubMed:20833364}.
CC   -!- DOMAIN: The SMP-LTD domain is a barrel-like domain that binds
CC       glycerophospholipids in its interior; can bind two lipid molecules
CC       simultaneously. Binds a variety of lipids, including
CC       phosphatidylethanolamine, phosphatidylcholine and phosphatidylinositol
CC       (By similarity). {ECO:0000250|UniProtKB:A0FGR8}.
CC   -!- DISRUPTION PHENOTYPE: Morpholino-mediated knock-down causes severe
CC       trunk shortening, disruption of somatic muscle formation and impairs
CC       the expression of the mesodermal marker t/xBRA, similar to the effects
CC       of inhibition of fgf signaling. {ECO:0000269|PubMed:20833364}.
CC   -!- SIMILARITY: Belongs to the extended synaptotagmin family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC046701; AAH46701.1; -; mRNA.
DR   RefSeq; NP_001080586.1; NM_001087117.1.
DR   AlphaFoldDB; Q7ZWU7; -.
DR   SMR; Q7ZWU7; -.
DR   GeneID; 380278; -.
DR   KEGG; xla:380278; -.
DR   CTD; 380278; -.
DR   Xenbase; XB-GENE-5932792; esyt2.L.
DR   OrthoDB; 52746at2759; -.
DR   Proteomes; UP000186698; Chromosome 6L.
DR   Bgee; 380278; Expressed in spleen and 19 other tissues.
DR   GO; GO:0140268; C:endoplasmic reticulum-plasma membrane contact site; ISS:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031227; C:intrinsic component of endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0044232; C:organelle membrane contact site; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0031210; F:phosphatidylcholine binding; ISS:UniProtKB.
DR   GO; GO:0008429; F:phosphatidylethanolamine binding; ISS:UniProtKB.
DR   GO; GO:0035091; F:phosphatidylinositol binding; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0061817; P:endoplasmic reticulum-plasma membrane tethering; IEA:InterPro.
DR   GO; GO:0006869; P:lipid transport; IEA:UniProtKB-KW.
DR   CDD; cd08391; C2A_C2C_Synaptotagmin_like; 1.
DR   CDD; cd04050; C2B_Synaptotagmin-like; 1.
DR   CDD; cd04030; C2C_KIAA1228; 1.
DR   Gene3D; 2.60.40.150; -; 3.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR037752; C2C_KIAA1228.
DR   InterPro; IPR037733; Ext_Synaptotagmin_C2A.
DR   InterPro; IPR037749; Ext_Synaptotagmin_C2B.
DR   InterPro; IPR031468; SMP_LBD.
DR   InterPro; IPR039010; Synaptotagmin_SMP.
DR   Pfam; PF00168; C2; 3.
DR   Pfam; PF17047; SMP_LBD; 1.
DR   SMART; SM00239; C2; 3.
DR   SUPFAM; SSF49562; SSF49562; 3.
DR   PROSITE; PS50004; C2; 3.
DR   PROSITE; PS51847; SMP; 1.
PE   2: Evidence at transcript level;
KW   Calcium; Cell membrane; Endocytosis; Endoplasmic reticulum;
KW   Lipid transport; Lipid-binding; Membrane; Metal-binding;
KW   Reference proteome; Repeat; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..876
FT                   /note="Extended synaptotagmin-2-B"
FT                   /id="PRO_0000278261"
FT   TOPO_DOM        1..35
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        36..56
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        57..59
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        60..80
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        81..876
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          123..302
FT                   /note="SMP-LTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01194"
FT   DOMAIN          301..421
FT                   /note="C2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          446..592
FT                   /note="C2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          741..863
FT                   /note="C2 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          614..714
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          788..795
FT                   /note="Required for phosphatidylinositol 4,5-bisphosphate-
FT                   dependent location at the cell membrane"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        635..653
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        665..701
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         332
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         333
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         333
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         345
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         392
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         392
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         393
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         394
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         394
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         394
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250"
FT   BINDING         396
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250"
FT   BINDING         398
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250"
FT   BINDING         399
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
SQ   SEQUENCE   876 AA;  98434 MW;  55560141069CA82E CRC64;
     MASESGAEKG PPTTPAENGQ PGVPIAAAVA ADEQGMISVD IAGLFYQFSK TFILIFPVYV
     LGYFGLSFSW LLIALVLLLW WRRNKGNKNS RLYRALAFLE TEEKSVKHHI ASIDLPAWVH
     FPDIERAEWL NKTVKHMWPY ICQFIEKLFR ETIEPAVRGA NAHLSTFSFT KIDMGSQPLR
     INGVKVYTEN VDKRQIILDL QISFVGETEI DLEVKRYFCR AGVKSIQLHG TMRVILEPLI
     GDVPIVGALS IFFLRKPLLE INWTGLTNML DMPGLNGLSD TIILDIISNY LVLPNRITVP
     LVSDVQIAQL RFPIPKGVLR IHFLEAQDLM WKDTYMKGLV KGKSDPYGVV RLGNQVFQSK
     VIKENLNPKW NEVYEALVHE HPGQELEIEL FDEDTDKDDF LGSLLIDLVE VEKERVVDEW
     FTLDEATSGK LHLKLEWLTP KSTTENLDQV LKSIKADKDQ ANDGLSAALL ILYLDSARSL
     PNNPLEINHD GMKKAAVEKA KKAGKKIGSS PNPYVLFSVG HTVQESKVKY KTAEPVWEQT
     FTFFVHNPKR QDLEVEVKDE NHQNSMGNIK IPLSQILASE DLTLNQRFHL NNSGPNSSLK
     MKIALRILHV EKPVRSPDEQ HTSQVKRPSI FKGKQPPTPQ MPAPSPAVAH KPPPTPKLET
     NKKLENGNKS STPSASPKRP TELHKSSSSL SGSSFTYSPP HLPTKEPTPS IASDISLPVA
     TQELRERLRQ LQNGTTLGQS PLGQIQLTIR HSSQRNKLMV VVHSCRNLIA FSEEGSDPYV
     RIYLLPDKRR SGRRKTHVHK RTLNPIYDQT FEFSVSLADL QRRTLDVAVK NGGGFLFREK
     GLLGKLLLEI NTEDAAKGWT QWFDLTEDGT RAAASS
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024